Is Bio-Techne Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, including a P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting Bio-Techne's premium valuation relative to its industry.
The company's recent stock performance has been underwhelming, with a year-to-date return of -14.12%, contrasting sharply with the S&P 500's gain of 13.30% over the same period. Additionally, over the past three years, Bio-Techne's stock has declined by 79.11%, while the S&P 500 has increased by 81.19%, further reinforcing the notion that the stock is overvalued in its current state.